NCT05283382 Cannabidiol Effects on Learning and Anxiety
| NCT ID | NCT05283382 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Connecticut |
| Condition | Anxiety and Fear |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-10-30 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 160 participants in total. It began in 2024-10-30 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.
Eligibility Criteria
Inclusion Criteria: * 18-50 years of age Exclusion Criteria: 1. Difficulties seeing a computer screen 2. Anyone currently taking CBD within the last 24 hours. 3. Anyone using any cannabis product within the last 24 hours. 4. Heart problems or heart disease 5. A neurological disorder such as epilepsy, stroke, multiple sclerosis, tumor, vascular malformations, aneurysm 6. Are currently pregnant or breast-feeding
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05283382 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Anxiety and Fear. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05283382 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05283382 currently recruiting?
Yes, NCT05283382 is actively recruiting participants. Contact the research team at robert.astur@uconn.edu for enrollment information.
Where is the NCT05283382 trial being conducted?
This trial is being conducted at Storrs, United States.
Who is sponsoring the NCT05283382 clinical trial?
NCT05283382 is sponsored by University of Connecticut. The trial plans to enroll 160 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.